Novartis AG may have just won eight more years of market exclusivity for its oral multiple sclerosis drug Gilenya (fingolimod), but the victory also was important for Celgene Corp., which will seek approval for its competing S1P receptor modulator ozanimod next year.
Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
